Adding velbicovir does not improve HBV markers in virologically suppressed patients

Key points:

• Triple therapy with virbicovir, educilan, and a nucleos
  
  

  He continued, “We all know that (nucleos

  Source/Disclosure

  collapse

  source:

  Feng SK, et al. Preliminary discontinuation reactions after 48 weeks of combination therapy with virbicovir, a nucleos

  
  Disclosure: Fung reports financial relationships with AbbVie, Gilead Sciences, Lupine, Novo Nordisk and Pfizer.

  
  

  
  
  Add topics to email alerts
  

  Receive emails when new articles are published

  Please provide your email address to receive an email when new articles are published .

  “data-action=”Subscribe”>Subscribe
  

  We are unable to process your request. Please try again later. If you are still experiencing this issue, please contact customerservice@slackinc.com.

  Back to Helio

  
  

  liver meeting